Exact Mass: 431.2705
Exact Mass Matches: 431.2705
Found 500 metabolites which its exact mass value is equals to given mass value 431.2705
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
alpha-hydroxysalmeterol
alpha-hydroxysalmeterol is a metabolite of salmeterol. Salmeterol is a long-acting beta2-adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease(COPD). It is currently available as a dry powder inhaler that releases a powdered form of the drug. Before 2008, it was also available as a metered-dose inhaler (MDI). (Wikipedia)
N-Docosahexaenoyl Cysteine
N-docosahexaenoyl cysteine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Docosahexaenoyl amide of Cysteine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Docosahexaenoyl Cysteine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Docosahexaenoyl Cysteine is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
N-Eicosapentaenoyl Glutamic acid
N-eicosapentaenoyl glutamic acid belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Eicosapentaenoic acid amide of Glutamic acid. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Eicosapentaenoyl Glutamic acid is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Eicosapentaenoyl Glutamic acid is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
Aglepristone
5-acetyloxy-2-amino-3,4,14-trihydroxyicos-6-enoic acid
2-acetamido-3,4,5,14-tetrahydroxyicos-6-enoic acid
Phomacin B
A cytochalasin isolated from a fungus Phoma sp. that has been shown to possess potent inhibitory activity against HT-29 colonic adenocarcinoma cells.
Phomacin A
A cytochalasin isolated from a fungus Phoma sp. that has been shown to possess potent inhibitory activity against HT-29 colonic adenocarcinoma cells.
2-(diaminomethylideneamino)-3,4,5,14-tetrahydroxyicos-6-enoic acid
Ala Thr Ile Lys
(E,2S,3R,4R,5S)-2-acetamido-3,4,5,14-tetrahydroxyicos-6-enoic acid
3-hydroxy-2-[[3-(3-hydroxy-6-methyloctanoyl)oxy-8-methylnonanoyl]amino]propanoic acid
(E,2S,3R,4R,5S)-4-acetyloxy-2-amino-3,5,14-trihydroxyicos-6-enoic acid
(E,2S,3R,4R,5S)-4-acetyloxy-2-amino-3,5,14-trihydroxyicos-6-enoic acid
(E,2S,3R,4R,5S)-4-acetyloxy-2-amino-3,5,14-trihydroxyicos-6-enoic acid [IIN-based on: CCMSLIB00000847931]
3-hydroxy-2-[[3-(3-hydroxy-6-methyloctanoyl)oxy-8-methylnonanoyl]amino]propanoic acid [IIN-based on: CCMSLIB00000848436]
3-hydroxy-2-[[3-(3-hydroxy-6-methyloctanoyl)oxy-8-methylnonanoyl]amino]propanoic acid [IIN-based: Match]
(E,2S,3R,4R,5S)-4-acetyloxy-2-amino-3,5,14-trihydroxyicos-6-enoic acid [IIN-based: Match]
(E,2S,3R,4R,5S)-4-acetyloxy-2-amino-3,5,14-trihydroxyicos-6-enoic acid_major
(E,2S,3R,4R,5S)-4-acetyloxy-2-amino-3,5,14-trihydroxyicos-6-enoic acid_97.3\\%
Ala Asp Lys Val
Ala Asp Val Lys
Ala Ile Lys Thr
Ala Ile Gln Thr
Ala Ile Thr Lys
Ala Ile Thr Gln
Ala Lys Asp Val
Ala Lys Ile Thr
Ala Lys Leu Thr
Ala Lys Thr Ile
Ala Lys Thr Leu
Ala Lys Val Asp
Ala Leu Lys Thr
Ala Leu Gln Thr
Ala Leu Thr Lys
Ala Leu Thr Gln
Ala Gln Ile Thr
Ala Gln Leu Thr
Ala Gln Thr Ile
Ala Gln Thr Leu
Ala Arg Ser Val
Ala Arg Val Ser
Ala Ser Arg Val
Ala Ser Val Arg
Ala Thr Ile Gln
Ala Thr Lys Ile
Ala Thr Lys Leu
Ala Thr Leu Lys
Ala Thr Leu Gln
Ala Thr Gln Ile
Ala Thr Gln Leu
Ala Val Asp Lys
Ala Val Lys Asp
Ala Val Arg Ser
Ala Val Ser Arg
Asp Ala Lys Val
Asp Ala Val Lys
Asp Gly Ile Lys
Asp Gly Lys Ile
Asp Gly Lys Leu
Asp Gly Leu Lys
Asp Ile Gly Lys
Asp Ile Lys Gly
Asp Lys Ala Val
Asp Lys Gly Ile
Asp Lys Gly Leu
Asp Lys Ile Gly
Asp Lys Leu Gly
Asp Lys Val Ala
Asp Leu Gly Lys
Asp Leu Lys Gly
Asp Val Ala Lys
Asp Val Lys Ala
Glu Gly Lys Val
Glu Gly Val Lys
Glu Lys Gly Val
Glu Lys Val Gly
Glu Val Gly Lys
Glu Val Lys Gly
Gly Asp Ile Lys
Gly Asp Lys Ile
Gly Asp Lys Leu
Gly Asp Leu Lys
Gly Glu Lys Val
Gly Glu Val Lys
Gly Ile Asp Lys
Gly Ile Lys Asp
Gly Ile Arg Ser
Gly Ile Ser Arg
Gly Lys Asp Ile
Gly Lys Asp Leu
Gly Lys Glu Val
Gly Lys Ile Asp
Gly Lys Leu Asp
Gly Lys Val Glu
Gly Leu Asp Lys
Gly Leu Lys Asp
Gly Leu Arg Ser
Gly Leu Ser Arg
Gly Arg Ile Ser
Gly Arg Leu Ser
Gly Arg Ser Ile
Gly Arg Ser Leu
Gly Arg Thr Val
Gly Arg Val Thr
Gly Ser Ile Arg
Gly Ser Leu Arg
Gly Ser Arg Ile
Gly Ser Arg Leu
Gly Thr Arg Val
Gly Thr Val Arg
Gly Val Glu Lys
Gly Val Lys Glu
Gly Val Arg Thr
Gly Val Thr Arg
Ile Ala Lys Thr
Ile Ala Gln Thr
Ile Ala Thr Lys
Ile Ala Thr Gln
Ile Asp Gly Lys
Ile Asp Lys Gly
Ile Gly Asp Lys
Ile Gly Lys Asp
Ile Gly Arg Ser
Ile Gly Ser Arg
Ile Lys Ala Thr
Ile Lys Asp Gly
Ile Lys Gly Asp
Ile Lys Thr Ala
Ile Asn Ser Val
Ile Asn Val Ser
Ile Gln Ala Thr
Ile Gln Thr Ala
Ile Arg Gly Ser
Ile Arg Ser Gly
Ile Ser Gly Arg
Ile Ser Asn Val
Ile Ser Arg Gly
Ile Ser Val Asn
Ile Thr Ala Lys
Ile Thr Ala Gln
Ile Thr Lys Ala
Ile Thr Gln Ala
Ile Val Asn Ser
Ile Val Ser Asn
Lys Ala Asp Val
Lys Ala Ile Thr
Lys Ala Leu Thr
Lys Ala Thr Ile
Lys Ala Thr Leu
Lys Ala Val Asp
Lys Asp Ala Val
Lys Asp Gly Ile
Lys Asp Gly Leu
Lys Asp Ile Gly
Lys Asp Leu Gly
Lys Asp Val Ala
Lys Glu Gly Val
Lys Glu Val Gly
Lys Gly Asp Ile
Lys Gly Asp Leu
Lys Gly Glu Val
Lys Gly Ile Asp
Lys Gly Leu Asp
Lys Gly Val Glu
Lys Ile Ala Thr
Lys Ile Asp Gly
Lys Ile Gly Asp
Lys Ile Thr Ala
Lys Leu Ala Thr
Lys Leu Asp Gly
Lys Leu Gly Asp
Lys Leu Thr Ala
Lys Pro Ser Thr
Lys Pro Thr Ser
Lys Ser Pro Thr
Lys Ser Thr Pro
Lys Ser Val Val
Lys Thr Ala Ile
Lys Thr Ala Leu
Lys Thr Ile Ala
Lys Thr Leu Ala
Lys Thr Pro Ser
Lys Thr Ser Pro
Lys Val Ala Asp
Lys Val Asp Ala
Lys Val Glu Gly
Lys Val Gly Glu
Lys Val Ser Val
Lys Val Val Ser
Leu Ala Lys Thr
Leu Ala Gln Thr
Leu Ala Thr Lys
Leu Ala Thr Gln
Leu Asp Gly Lys
Leu Asp Lys Gly
Leu Gly Asp Lys
Leu Gly Lys Asp
Leu Gly Arg Ser
Leu Gly Ser Arg
Leu Lys Ala Thr
Leu Lys Asp Gly
Leu Lys Gly Asp
Leu Lys Thr Ala
Leu Asn Ser Val
Leu Asn Val Ser
Leu Gln Ala Thr
Leu Gln Thr Ala
Leu Arg Gly Ser
Leu Arg Ser Gly
Leu Ser Gly Arg
Leu Ser Asn Val
Leu Ser Arg Gly
Leu Ser Val Asn
Leu Thr Ala Lys
Leu Thr Ala Gln
Leu Thr Lys Ala
Leu Thr Gln Ala
Leu Val Asn Ser
Leu Val Ser Asn
Asn Ile Ser Val
Asn Ile Val Ser
Asn Leu Ser Val
Asn Leu Val Ser
Asn Ser Ile Val
Asn Ser Leu Val
Asn Ser Val Ile
Asn Ser Val Leu
Asn Thr Val Val
Asn Val Ile Ser
Arg Ala Ser Val
Arg Ala Val Ser
Arg Gly Ile Ser
Arg Gly Leu Ser
Arg Gly Ser Ile
Arg Gly Ser Leu
Arg Gly Thr Val
Arg Gly Val Thr
Arg Ile Gly Ser
Arg Ile Ser Gly
Arg Leu Gly Ser
Arg Leu Ser Gly
Arg Ser Ala Val
Arg Ser Gly Ile
Arg Ser Gly Leu
Arg Ser Ile Gly
Arg Ser Leu Gly
Arg Ser Val Ala
Arg Thr Gly Val
Arg Thr Val Gly
Arg Val Ala Ser
Arg Val Gly Thr
Arg Val Ser Ala
Arg Val Thr Gly
Ser Ala Arg Val
Ser Ala Val Arg
Ser Gly Ile Arg
Ser Gly Leu Arg
Ser Gly Arg Ile
Ser Gly Arg Leu
Ser Ile Gly Arg
Ser Ile Arg Gly
Ser Lys Val Val
Ser Leu Gly Arg
Ser Leu Arg Gly
Ser Arg Ala Val
Ser Arg Gly Ile
Ser Arg Gly Leu
Ser Arg Ile Gly
Ser Arg Leu Gly
Ser Arg Val Ala
Ser Val Ala Arg
Ser Val Lys Val
Ser Val Arg Ala
Ser Val Val Lys
Thr Ala Ile Lys
Thr Ala Lys Ile
Thr Ala Lys Leu
Thr Ala Leu Lys
Thr Gly Arg Val
Thr Gly Val Arg
Thr Ile Ala Lys
Thr Ile Lys Ala
Thr Lys Ala Ile
Thr Lys Ala Leu
Thr Lys Ile Ala
Thr Lys Leu Ala
Thr Leu Ala Lys
Thr Leu Lys Ala
Thr Arg Gly Val
Thr Arg Val Gly
Thr Val Gly Arg
Thr Val Arg Gly
Val Ala Arg Ser
Val Ala Ser Arg
Val Gly Arg Thr
Val Gly Thr Arg
Val Lys Ser Val
Val Lys Val Ser
Val Arg Ala Ser
Val Arg Gly Thr
Val Arg Ser Ala
Val Arg Thr Gly
Val Ser Ala Arg
Val Ser Lys Val
Val Ser Arg Ala
Val Ser Val Lys
Val Thr Gly Arg
Val Thr Arg Gly
Val Val Lys Ser
Val Val Ser Lys
[4-[bis[4-(dimethylamino)phenyl]methylene]-2,5-cyclohexadien-1-ylidene]dimethylammonium acetate
dodecyl benzenesulfonate,2-(2-hydroxyethylamino)ethanol
Tris(4-tert-butylphenyl)sulfoniumperfluoro-1-butanesulfonate
(R)-2-((9-ISOPROPYL-6-((3-(PYRIDIN-2-YL)BENZYL)AMINO)-9H-PURIN-2-YL)AMINO)BUTAN-1-OL
1-[(2R)-2-amino-3-(4-fluorophenyl)propanoyl]-N-tert-butyl-4-cyclo hexyl-piperidine-4-carboxamide
6-AMINO-5-(2,2-DIETHOXYETHYL)-2-((4-(2-(PYRROLIDIN-1-YL)ETHOXY)PHENYL)AMINO)PYRIMIDIN-4(3H)-ONE
2-[2-[4-[(2-cyanoethyl)ethylamino]-o-tolyl]vinyl]-1,3,3-trimethyl-3H-indolium acetate
8-Cyclopentyl-5-methyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}-6-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
1-Butyl-5-[2-(1-butyl-3,3-dimethyl-1,3-dihydroindol-2-ylidene)ethylidene]-4-methyl-2,6-dioxo-1,2,5,6-tetrahydropyridine-3-carbonitrile
Aglepristone
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C1891 - Progesterone Antagonist
(2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol
(2S)-2-[[9-propan-2-yl-6-[[4-(2-pyridinyl)phenyl]methylamino]-2-purinyl]amino]-1-butanol
Splenotritin
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones
1,5-Anhydro-2-C-(carboxymethyl-N-hydroxyamide)-2-deoxy-3-O-myristoyl-D-glucitol
4,4-Diaponeurosporenoate
A monocarboxylic acid anion that is the conjugate base of 4,4-diaponeurosporenoic acid, obtained by deprotonation of the carboxy group. Major structure at pH 7.3.
11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-[(Z)-prop-1-enyl]-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
[1-[1-[[5-(2-methylpropyl)-1H-pyrazol-3-yl]-oxomethyl]-4-piperidinyl]-4-piperidinyl]-(4-morpholinyl)methanone
(E,2S,3R,4R,5S)-2-Acetamido-3,4,5,14-tetrahydroxyicos-6-enoic acid
1-(3-Carboxypropyl)-9-(dimethylamino)-2,2,4,11,11-pentamethyl-2,11-dihydronaphtho[2,3-g]quinolinium
N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-(2-oxo-2-piperidin-1-ylethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-2-(dimethylamino)acetamide
N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide
N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide
N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide
N-[(2S,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclohexanecarboxamide
N-[[(2S,3S)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide
N-[[(2R,3R)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide
N-[[(2S,3R)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
N-[(5R,6S,9R)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
N-[(5R,6R,9R)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4S,7S,8S)-5-[cyclopropyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(4R,7S,8S)-5-[cyclopropyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(4R,7S,8R)-5-[cyclopropyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide
[(1R)-1-(cyclopropylmethyl)-7-methoxy-9-methyl-2-(phenylmethyl)-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol
3-Hydroxy-2-[[3-(3-hydroxy-6-methyloctanoyl)oxy-8-methylnonanoyl]amino]propanoic acid
N-[(2R,3S)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclohexanecarboxamide
N-[(2S,3R)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]cyclohexanecarboxamide
N-[[(2R,3S)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide
N-[[(2S,3R)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide
N-[[(2R,3R)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide
N-[[(2R,3S)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide
N-[[(2S,3S)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-2-methoxy-N-methylacetamide
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
N-[(5S,6S,9S)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(5S,6S,9R)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
N-[(5R,6R,9S)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4R,7R,8S)-5-[cyclopropyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(4R,7R,8R)-5-[cyclopropyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(4S,7R,8R)-5-[cyclopropyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(4S,7S,8R)-5-[cyclopropyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(4S,7R,8S)-5-[cyclopropyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide
N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide
[(1S)-1-(cyclopropylmethyl)-7-methoxy-9-methyl-2-(phenylmethyl)-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol
(3R)-17-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyheptadecanoate
(3R,16R)-16-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyheptadecanoate
2-aminoethyl [3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]-2-hydroxypropyl] hydrogen phosphate
(4E,8E)-2-(decanoylamino)-3-hydroxydodeca-4,8-diene-1-sulfonic acid
4-(3-Butanoyloxy-2-octanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-[2,3-Di(hexanoyloxy)propoxy]-2-(trimethylazaniumyl)butanoate
4-(2-Heptanoyloxy-3-pentanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(2-Nonanoyloxy-3-propanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(3-Acetyloxy-2-decanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
2-(3-Trimethylsilyloxybutoxy)-N-(2-(diethylamino)ethyl)-4-quinolinecarboxamide
ATTO 635-2(1+)
The cationic form of a fluorescent dye derived from a tetrahydronaphtho[2,3-g]quinoline.